Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Evaluation of Incidence of Myelosuppression (Grade 4 Neutropenia) in Breast Cancer Patients With Mild, Moderate or Severe Hepatic Impairment Treated With Palbociclib Compared to Patients With Reserved Hepatic Function in the Post-marketing Setting: Cohort Study Using the Medical Information Database Network (MID-NET) Database

NCT05912933 is registered in ClinicalTrials.gov with Pfizer as lead sponsor.

NCT NCT05912933
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05912933 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Evaluation of Incidence of Myelosuppression (Grade 4 Neutropenia) in Breast Cancer Patients With Mild, Moderate or Severe Hepatic Impairment Treated With Palbociclib Compared to Patients With Reserved Hepatic Function in the Post-marketing Setting: Cohort Study Using the Medical Information Database Network (MID-NET) Database
Lead sponsor
Pfizer
Phase
Observational
Overall status
Completed
Start date
August 19, 2024
Completion date
August 30, 2024
Enrollment
1,342 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer